PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients.

[1]  C. Porta,et al.  Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. , 2021, The New England journal of medicine.

[2]  G. Giaccone,et al.  DURABLE RESPONSE IN PATIENTS WITH THYMIC CARCINOMA TREATED WITH PEMBROLIZUMAB AFTER PROLONGED FOLLOW-UP. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  N. Girard,et al.  1899P Autoimmune diseases in centrally reviewed thymic epithelial tumours (TET) , 2020 .

[4]  Tomoaki Yamada,et al.  Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial. , 2020, The Lancet. Oncology.

[5]  E. Schmidt,et al.  Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Mammen,et al.  Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma , 2019, Journal of Immunotherapy for Cancer.

[7]  J. Ahn,et al.  Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Y. Hosomi,et al.  Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study. , 2019, European journal of cancer.

[9]  C. Yiannoutsos,et al.  A Phase II Study of Pemetrexed in Patients with Recurrent Thymoma and Thymic Carcinoma , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  N. Girard,et al.  Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  Dai Fukumura,et al.  Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges , 2018, Nature Reviews Clinical Oncology.

[12]  G. Giaccone,et al.  Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. , 2018, The Lancet. Oncology.

[13]  D. Planchard,et al.  Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience. , 2016, Lung cancer.

[14]  N. Girard,et al.  The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  P. Meltzer,et al.  Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. , 2015, The Lancet. Oncology.

[16]  A. Nicholson,et al.  The Impact of Thymoma Histotype on Prognosis in a Worldwide Database , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  A. Chella,et al.  Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Y. Matsuzaki,et al.  Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors. , 2002, The Journal of thoracic and cardiovascular surgery.